Genmab’s $8B Bet: Denmark’s Antibody Champion Buys Dutch Merus to Build Oncology Powerhouse
In late September 2025, Danish biotech company Genmab announced its acquisition of Merus , a Netherlands-based, U.S.-listed oncology biotech, in an all-cash deal valued at around $8 billion . The transaction, expected to close in early 2026, represents a roughly 40 percent premium to Merus’s share price at the time of announcement and marks one of the largest European biotech acquisitions of the year.
Merus was founded in 2003 in Utrecht by Dutch immunologist Ton Logtenberg, who envisioned engineering antibodies capable of binding to multiple targets at once. Spun out from academic research at Utrecht University, the company became a pioneer in bispecific antibody technology—laying the groundwork for what would become its Multiclonics platform.
Merus, long regarded as one of Europe’s most innovative antibody startups, built its reputation around multispecific antibody platforms—branded as Multiclonics, Biclonics, and Triclonics—that can target multiple disease pathways simultaneously. Its lead drug candidate, petosemtamab , is a bispecific antibody that targets EGFR and LGR5, showing encouraging results in head and neck cancers and drawing comparisons to some of the most successful immuno-oncology therapies of the past decade. Merus’s pipeline also includes zenocutuzumab , developed for cancers driven by NRG1 gene fusions, and several earlier-stage programs developed independently or through collaborations with major partners such as Gilead. The company’s steady progress, combined with a public offering earlier in 2025 and promising Phase 2 results for petosemtamab, had positioned it as a prime takeover target.
For Genmab, the deal is both strategic and symbolic. The Danish company is best known for its antibody expertise and for discovering Darzalex , the blockbuster cancer therapy now commercialized by Johnson & Johnson. Until recently, Genmab’s business model relied heavily on partnerships and royalty income, but in recent years it has aimed to own and commercialize more of its own drugs. The acquisition of Merus, therefore, represents a shift from being a licensing powerhouse to becoming a fully integrated oncology player with a deeper proprietary pipeline.
The rationale for the acquisition centers on three key ideas. First, Merus gives Genmab control over a potentially transformative late-stage oncology asset in petosemtamab, which could reach the market in the next few years. Second, it diversifies Genmab’s revenue base beyond royalties and reinforces its ambition to stand among the global leaders in cancer therapeutics. Third, it leverages Genmab’s global clinical, regulatory, and commercial infrastructure to accelerate Merus’s programs and maximize their value. The timing is also strategic: with Phase 3 trials underway, Genmab is positioning itself ahead of possible positive readouts, securing full upside if the data confirm petosemtamab’s potential.
Still, the deal carries clear risks. The success of petosemtamab depends on clinical outcomes yet to be seen, and Genmab’s willingness to pay a substantial premium reflects a high level of confidence that may not be universally shared. Integrating Merus’s operations and talent, managing overlapping R&D portfolios, and financing the acquisition—partly through new debt—add layers of execution risk. If the Phase 3 results disappoint, the valuation could quickly look excessive.
In essence, Genmab’s purchase of Merus is a bet on scientific conviction and strategic evolution. It underscores the growing consolidation in European biotech and the push among leading antibody developers to own breakthrough platforms outright. For Merus, the deal validates over a decade of research into bispecific antibody engineering. For Genmab, it signals a determination to control more of its own destiny in oncology—turning from a behind-the-scenes collaborator into a company intent on shaping the next generation of cancer therapeutics.
